SAN FRANCISCO, April 19, 2018 /PRNewswire/ --
The global c-reactive protein (CRP) testing
market size is expected to reach USD 1.77 billion by 2025, according to a new
report by Grand View Research, Inc., exhibiting a CAGR of 1.3%
during the forecast period. Rising incidence of inflammatory
disorders such as cancer infections and cardiovascular disorders is
one of the leading factors driving market growth. Furthermore,
increasing global incidence of endometriosis in women is expected
to play a major role in the CRP testing market over the forecast
period.
(Logo:
https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg
)
Increase in funds provided to academic research institutions and
individual researchers is expected to boost growth. Moreover,
various initiatives by international bodies such as WHO and NIH for
prevention and treatment of chronic disorders such as
cardiovascular diseases and cancer are anticipated to promote
growth.
Point-of-care devices for CRP testing are being increasingly
adopted by healthcare professionals in clinics and hospitals.
Technological advancements in these portable, rapid, and
easy-to-use testing devices are expected to strengthen POC
settings. Additionally, collaborations among governments,
companies, and research institutions are expected to drive the
growth of CRP diagnostic devices.
Browse full research report with TOC on
"C-Reactive Protein (CRP) Test Market Size, Share &
Trends Analysis Report By Assay Type, By Detection Range, By
Disease Area (Cardiovascular Disease, Cancer, Rheumatoid
Arthritis), By End Use, And Segment Forecasts, 2018 -
2025" at:
https://www.grandviewresearch.com/industry-analysis/global-c-reactive-protein-testing-market
Further Key Findings From the Report Suggest:
- By type of assay, immunoturbidimetric assays are estimated to
account for the largest revenue share owing to adequate
availability of CRP testing kits based on this technology
- Based on disease type, cardiovascular disorders accounted for
the largest market share owing to higher clinical significance of
CRP levels in disease-oriented studies for cardiac infections and
strokes
- On the basis of end use, clinics are estimated to account for
the largest share in terms of revenue, owing to favorable
government policies in the field of primary healthcare
settings
- North America dominated the
market due to presence of a well-established healthcare framework,
government support, increase in investigational studies in this
field, and presence of a substantial number of regional
players
- Asia Pacific is expected to
exhibit the fastest growth over the forecast period owing to
presence of local as well as international market players,
extensive research, and favorable government support
- Major players include Thermo Fisher Scientific, Inc.; F
Hoffmann-La Roche Ltd.; Ortho Clinical Diagnostics; Quest
Diagnostics; Danaher; Siemens Healthineers; Abbott; Abaxis, Inc.;
Merck & Co., Inc.; Laboratory Corporation of America Holdings;
Getein Biotech, Inc.; Randox Laboratories Ltd.; BODITECH MED, INC.;
Orion Diagnostica Oy; and HORIBA, Ltd.
- Companies are entering into collaborations with academic
institutions and private and public entities to promote
advancements in the space, which is ultimately driving the growth
of the C-reactive protein testing market.
Browse related reports by Grand View Research:
- Genetic Disease Diagnostic Market - Rising
incidences of genetic disorders that give rise to wide variety of
independent diagnostic procedures globally is predominantly driving
the growth of the global genetic disorder diagnostic
market.
- Autoimmune Disease Diagnostics Market - The global
autoimmune disease diagnostics market size was valued at
USD 3.3 billion in the year 2015 and
is estimated to reach a value of USD 5.0
billion by 2025
- Nucleic Acid Amplification Testing Market - The global
nucleic acid amplification testing (NAAT) market size was valued at
USD 1.78 billion in 2015 and is
expected to reach USD 4.4 Billion by
2025
- Cancer Diagnostics Market - The global cancer
diagnostics market size was valued at USD
124.0 billion in 2016 and is expected to grow at a CAGR of
7.2% over the forecast period.
Grand View Research has segmented the global C-reactive
protein testing market on the basis of assay type, detection range,
disease area, end use, and region:
- C-Reactive Protein Testing Assay Type
Outlook (Revenue, USD Million, 2014 - 2025)
- Immunoturbidimetric assay
- ELISA
- Chemiluminescence immunoassay (CLIA)
- Others
- C-Reactive Protein Testing Detection Range Outlook (Revenue,
USD Million, 2014 - 2025)
- hs-CRP
- Conventional CRP
- cCRP
- C-Reactive Protein Testing Disease Area Outlook (Revenue,
USD Million, 2014 - 2025)
- Cardiovascular diseases
- Cancer
- Rheumatoid arthritis
- Inflammatory bowel disease
- Endometriosis
- Lupus
- Others
- C-Reactive Protein Testing End-use Outlook (Revenue, USD
Million, 2014 - 2025)
- Clinics
- Hospitals
- Laboratories
- Assisted living healthcare facilities
- Home
- Others
- C-Reactive Protein Testing Regional Outlook (Revenue, USD
Million, 2014 - 2025)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Read Our Blog By Grand View Research:
https://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company
provides syndicated research reports, customized research reports,
and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant
and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com